Dr. Tianhong Li, MD, PhD

Dr. Li practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Li's NPI, 1588744072, was assigned on October 17, 2006. Dr. Li graduated from Beijing Medical University in 1989. Dr. Li holds California license C53681.

Dr. Li's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Li's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Li practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Li's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Li is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Li's licenses on file in 2 states: California and New York.

Dmand AI lists breast cancer, colorectal cancer, lung cancer and multiple myeloma among the conditions Dr. Li treats.

CMS data shows 458 Medicare services from Dr. Li across 9 procedure codes in 2024, for 149 Medicare patients. Medicare paid $29,685 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 149 Medicare patients who saw Dr. Li in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have cancer, and 72% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Li's median patient age at 70, with 66% women.

In 2024, Dr. Li wrote 544 Medicare Part D claims for 70 patients. 48% of them were for generic drugs. CMS names the drug for 427 of them, across 16 drugs with 11 or more claims each, at $3,468,172 in total drug cost. In 2023, CMS named 468 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Li for performance year 2024, reported as part of a group. Dr. Li accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Li as offering telehealth.

Dmand AI links 86 papers to Dr. Li, published from 2006 to 2024. 2022 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Li has published most often in Clin Lung Cancer. Dr. Li's most frequent co-authors are David Raymond Gandara, MD, Primo Nery Lara, MD and Ken Y. Yoneda, MD.

Dmand AI links Dr. Li to 11 clinical trials, 3 of them phase 1 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 89 general payments to Dr. Li from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Bristol-Myers Squibb Company paid the most, $6,750.

Dmand AI lists 1 award for Dr. Li, most recently CMS Stage 1 EHR in 2012.

Dr. Li graduated from Beijing Medical University in 1989. Dr. Li is a member of ASCO.

Dr. Li is in network with 7 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.